<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36010377</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>22</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Interstitial Lung Fibrosis Following COVID-19 Pneumonia.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics12082028</ELocationID><Abstract><AbstractText><i>Background and Objectives:</i> Pulmonary fibrosis represents a stage of normal physiologic response to inflammatory aggression, mostly self-limiting and reversible; however, numerous patients treated for SARS-CoV-2 pneumonia present after release from hospital residual lung fibrosis. In this article, we aim to present an optimization method for evaluating pulmonary fibrosis by quantitative analysis, to identify the risk factors/predictors for pulmonary fibrosis in patients with SARS-CoV-2 infection, and to characterize the impact of pulmonary fibrosis on the symptomatology of patients after release from the hospital. <i>Materials and Methods:</i> We performed a prospective observational study on 100 patients with severe forms of pneumonia, with a control group of 61 non-COVID normal patients. <i>Results:</i> We found persistent interstitial changes consistent with fibrotic changes in 69% of patients. The risk of fibrosis was proportional to the values of erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and lactate dehydrogenase (LDH), and to the duration of hospitalization. The imaging parameters correlated with increased risk for interstitial fibrosis were the number of affected pulmonary lobes and the percent of interstitial pulmonary fibrosis. <i>Conclusions:</i> The main risk factors for pulmonary fibrosis post-COVID-19 identified in our study are increased ESR, CRP, LDH, duration of hospitalization and the severity of pneumonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Mihai</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Prof. Dr. Matei Bals, No. 1, Calistrat Grozovici Street, Sector 2, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbu</LastName><ForeName>Ecaterina Constanta</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0001-9560-6264</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chitu</LastName><ForeName>Cristina Emilia</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiliscan</LastName><ForeName>Catalin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Prof. Dr. Matei Bals, No. 1, Calistrat Grozovici Street, Sector 2, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratan</LastName><ForeName>Laurentiu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arama</LastName><ForeName>Sorin Stefan</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arama</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Infectious Diseases Prof. Dr. Matei Bals, No. 1, Calistrat Grozovici Street, Sector 2, 021105 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ion</LastName><ForeName>Daniela Adriana</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, No. 37, Dionisie Lupu Street, Sector 2, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">fibrosis predictors</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">quantitative analysis</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36010377</ArticleId><ArticleId IdType="pmc">PMC9407299</ArticleId><ArticleId IdType="doi">10.3390/diagnostics12082028</ArticleId><ArticleId IdType="pii">diagnostics12082028</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382:1199&#x2013;1207. doi: 10.1056/NEJMoa2001316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L., Ruan F., Huang M., Liang L., Huang H., Hong Z., Yu J., Kang M., Song Y., Xia J., et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N. Engl. J. Med. 2020;382:1177&#x2013;1179. doi: 10.1056/NEJMc2001737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2001737</ArticleId><ArticleId IdType="pmc">PMC7121626</ArticleId><ArticleId IdType="pubmed">32074444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung-Chen Y., Algora-Mart&#xed;n A., Rodr&#xed;guez-Roca S., de Santiago A.D. COVID-19 multisystemic inflammatory syndrome in adults: A not to be missed diagnosis. BMJ Case Rep. 2021;14:e241696. doi: 10.1136/bcr-2021-241696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2021-241696</ArticleId><ArticleId IdType="pmc">PMC8051400</ArticleId><ArticleId IdType="pubmed">33849879</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslan A., Aslan C., Zolbanin N.M., Jafari R. Acute respiratory distress syndrome in COVID-19: Possible mechanisms and therapeutic management. Pneumonia. 2021;13:14. doi: 10.1186/s41479-021-00092-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41479-021-00092-9</ArticleId><ArticleId IdType="pmc">PMC8647516</ArticleId><ArticleId IdType="pubmed">34872623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., et al. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020&#x2013;2021. Lancet. 2022;399:1513&#x2013;1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Beurnier A., Colle R., No&#xeb;l N., Pham T., Monnet X., Humbert M. Multidisciplinary approach for post-acute COVID-19 syndrome: Time to break down the walls. Eur. Respir. J. 2021;58:2101090. doi: 10.1183/13993003.01090-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01090-2021</ArticleId><ArticleId IdType="pmc">PMC8112007</ArticleId><ArticleId IdType="pubmed">33958429</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin B.J.H., Kakamad F.H., Ahmed G.S., Ahmed S.F., Abdulla B.A., Mohammed S.H., Mikael T.M., Salih R.Q., Ali R.K., Salh A.M., et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Ann. Med. Surg. 2022;77 doi: 10.1016/j.amsu.2022.103590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103590</ArticleId><ArticleId IdType="pmc">PMC8983072</ArticleId><ArticleId IdType="pubmed">35411216</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai D.K., Kumar S., Sahay N. Post-COVID-19 pulmonary fibrosis: A case series and review of literature. J. Fam. Med. Prim. Care. 2021;10:2028&#x2013;2031. doi: 10.4103/jfmpc.jfmpc_2126_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_2126_20</ArticleId><ArticleId IdType="pmc">PMC8208181</ArticleId><ArticleId IdType="pubmed">34195143</ArticleId></ArticleIdList></Reference><Reference><Citation>Aul R., Gates J., Draper A., Dunleavy A., Ruickbie S., Meredith H., Walters N., van Zeller C., Taylor V., Bridgett M., et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir. Med. 2021;188:106602. doi: 10.1016/j.rmed.2021.106602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106602</ArticleId><ArticleId IdType="pmc">PMC8425673</ArticleId><ArticleId IdType="pubmed">34536697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J.N., Sun L., Wang B.R., Zou Y., Xu S., Ding Y.J., Shen L.J., Huang W.C., Jiang X.J., Chen S.M. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS ONE. 2021;16:e0248957. doi: 10.1371/journal.pone.0248957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0248957</ArticleId><ArticleId IdType="pmc">PMC7987145</ArticleId><ArticleId IdType="pubmed">33755708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson M.S., Wynn T.A. Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2:103&#x2013;121. doi: 10.1038/mi.2008.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2008.85</ArticleId><ArticleId IdType="pmc">PMC2675823</ArticleId><ArticleId IdType="pubmed">19129758</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestro E., Calabrese F., Turato G., Lunardi F., Bazzan E., Marulli G., Biondini D., Rossi E., Sanduzzi A., Rea F., et al. Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLoS ONE. 2016;11:e0154516. doi: 10.1371/journal.pone.0154516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154516</ArticleId><ArticleId IdType="pmc">PMC4861274</ArticleId><ArticleId IdType="pubmed">27159038</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.-F., Flaherty K.R., Lasky J.A., et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am. J. Respir. Crit. Care Med. 2011;183:788&#x2013;824. doi: 10.1164/rccm.2009-040GL.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.2009-040GL</ArticleId><ArticleId IdType="pmc">PMC5450933</ArticleId><ArticleId IdType="pubmed">21471066</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs S., Chung J., Leb J., Kaproth-Joslin K., Lynch D. Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation. Radiol. Cardiothorac. Imaging. 2021;3:e200279. doi: 10.1148/ryct.2021200279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.2021200279</ArticleId><ArticleId IdType="pmc">PMC7977697</ArticleId><ArticleId IdType="pubmed">33778653</ArticleId></ArticleIdList></Reference><Reference><Citation>Battista G., Sassi C., Zompatori M., Palmarini D., Canini R. Ground-glass opacity: Interpretation of high resolution CT findings. La Radiol. Med. 2004;106:425&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansell D.M., Bankier A.A., MacMahon H., McLoud T.C., M&#xfc;ller N.L., Remy J. Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology. 2008;246:697&#x2013;722. doi: 10.1148/radiol.2462070712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2462070712</ArticleId><ArticleId IdType="pubmed">18195376</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH)  COVID-19 Treatment Guidelines, Clinical Spectrum of SARS-CoV-2 Infection.  [(accessed on 4 June 2022)];2021  Available online:  https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</Citation></Reference><Reference><Citation>Anghel A.-M., Niculae C.-M., Manea E.-D., Lazar M., Popescu M., Damalan A.-C., Bel A.-A., Nedelcu I.-M., Patrascu R.-E., Hristea A. The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients. J. Clin. Med. 2022;11:1247. doi: 10.3390/jcm11051247.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051247</ArticleId><ArticleId IdType="pmc">PMC8911095</ArticleId><ArticleId IdType="pubmed">35268338</ArticleId></ArticleIdList></Reference><Reference><Citation>Leach H.G., Chrobak I., Han R., Trojanowska M. Endothelial Cells Recruit Macrophages and Contribute to a Fibrotic Milieu in Bleomycin Lung Injury. Am. J. Respir. Cell Mol. Biol. 2013;49:1093&#x2013;1101. doi: 10.1165/rcmb.2013-0152OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2013-0152OC</ArticleId><ArticleId IdType="pmc">PMC3931119</ArticleId><ArticleId IdType="pubmed">23885794</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasse A., Pechkovsky D.V., Toews G.B., Jungraithmayr W., Kollert F., Goldmann T., Vollmer E., M&#xfc;ller-Quernheim J., Zissel G. A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 2006;173:781&#x2013;792. doi: 10.1164/rccm.200509-1518OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200509-1518OC</ArticleId><ArticleId IdType="pubmed">16415274</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawata M., Koinuma D., Ogami T., Umezawa K., Iwata C., Watabe T., Miyazono K. TGF-&#x3b2;-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J. Biochem. 2011;151:205&#x2013;216. doi: 10.1093/jb/mvr136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvr136</ArticleId><ArticleId IdType="pubmed">22161143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., Chapman H.A. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. USA. 2006;103:13180&#x2013;13185. doi: 10.1073/pnas.0605669103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0605669103</ArticleId><ArticleId IdType="pmc">PMC1551904</ArticleId><ArticleId IdType="pubmed">16924102</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpino M.V., Quarleri J. SARS-CoV-2 Pathogenesis: Imbalance in the renin-angiotensin system favors lung fibrosis. Front. Cell Infect. Microbiol. 2020;10:340. doi: 10.3389/fcimb.2020.00340.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00340</ArticleId><ArticleId IdType="pmc">PMC7303284</ArticleId><ArticleId IdType="pubmed">32596170</ArticleId></ArticleIdList></Reference><Reference><Citation>Udwadia Z., Koul P., Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021;38:S41&#x2013;S47. doi: 10.4103/lungindia.lungindia_818_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/lungindia.lungindia_818_20</ArticleId><ArticleId IdType="pmc">PMC8104338</ArticleId><ArticleId IdType="pubmed">33686978</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh Y.J., Hong H., Ohana M., Bompard F., Revel M.-P., Valle C., Gervaise A., Poissy J., Susen S., H&#xe9;kimian G., et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2021;298:E70&#x2013;E80. doi: 10.1148/radiol.2020203557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020203557</ArticleId><ArticleId IdType="pmc">PMC7745997</ArticleId><ArticleId IdType="pubmed">33320063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran S., Ksajikian A., Overbey J., Li P., Li Y. Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review. Cells. 2022;11:2489. doi: 10.3390/cells11162489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162489</ArticleId><ArticleId IdType="pmc">PMC9406710</ArticleId><ArticleId IdType="pubmed">36010566</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Lv F., Huang Y., Xiao K. Follow-up study of the chest CT characteristics of COVID-19 survivors seven months after recovery. Front. Med. 2021;8:636298. doi: 10.3389/fmed.2021.636298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.636298</ArticleId><ArticleId IdType="pmc">PMC7956974</ArticleId><ArticleId IdType="pubmed">33732719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabahati M., Ebrahimpour S., Khaleghnejad Tabari R., Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: A prospective study. Egypt. J. Radiol. Nucl. Med. 2021;52:248. doi: 10.1186/s43055-021-00632-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00632-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E., Rusina P., Panova M., Novikov F., Grishagin I., Nebolsin V. Lung Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals. 2021;14:807. doi: 10.3390/ph14080807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14080807</ArticleId><ArticleId IdType="pmc">PMC8398080</ArticleId><ArticleId IdType="pubmed">34451904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.-M., Shang Y.-M., Song W.-B., Li Q.-Q., Xie H., Xu Q.-F., Jia J.-L., Li L.-M., Mao H.-L., Zhou X.-M., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. eClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>American Thoracic Society Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000;161:646&#x2013;664. doi: 10.1164/ajrccm.161.2.ats3-00.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.161.2.ats3-00</ArticleId><ArticleId IdType="pubmed">10673212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung K.T., Wells A.U., Rubens M.B., Kirk J.M., du Bois R.M., Hansell D.M. Accuracy of the typical computed tomographic appearances of fibrosingalveolitis. Thorax. 1993;48:334&#x2013;338. doi: 10.1136/thx.48.4.334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.48.4.334</ArticleId><ArticleId IdType="pmc">PMC464428</ArticleId><ArticleId IdType="pubmed">8135910</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenier P., Valeyre D., Cluzel P., Brauner M.W., Lenoir S., Chastang C. Chronic diffuse interstitial lung disease: Diagnostic value of chest radiography and high-resolution CT. Radiology. 1991;179:123&#x2013;132. doi: 10.1148/radiology.179.1.2006262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.179.1.2006262</ArticleId><ArticleId IdType="pubmed">2006262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunninghake G.W., Lynch D.A., Galvin J.R., Gross B.H., M&#xfc;ller N., Schwartz D.A., King T.E., Jr., Lynch J.P., 3rd, Hegele R., Waldron J., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003;124:1215&#x2013;1223. doi: 10.1378/chest.124.4.1215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.124.4.1215</ArticleId><ArticleId IdType="pubmed">14555549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kizer J., Zisman D., Blumenthal N., Kotloff R.M., Kimmel S.E., Strieter R.M., Arcasoy S.M., Ferrari V.A., Hansen-Flaschen J. Association between pulmonary fibrosis and coronary artery disease. Arch. Int. Med. 2004;164:551&#x2013;556. doi: 10.1001/archinte.164.5.551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.5.551</ArticleId><ArticleId IdType="pubmed">15006833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansell D.M., Goldin J.G., King T.E., Jr., Lynch D.A., Richeldi L., Wells A.U. CT staging and monitoring of fi brotic interstitial lung diseases in clinical practice and treatment trials: A Position Paper from the Fleischner Society. Lancet. 2015;3:483&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">25975761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunninghake G.W., Zimmerman M.B., Schwartz D.A., King T.E., Jr., Lynch J., Hegele R., Waldron J., Colby T., M&#xfc;ller N., Lynch D., et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001;164:193&#x2013;196. doi: 10.1164/ajrccm.164.2.2101090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.164.2.2101090</ArticleId><ArticleId IdType="pubmed">11463586</ArticleId></ArticleIdList></Reference><Reference><Citation>Swensen S.J., Aughenbaugh G.L., Myers J.L. Diffuse lung disease: Diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology. 1997;205:229&#x2013;234. doi: 10.1148/radiology.205.1.9314990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.205.1.9314990</ArticleId><ArticleId IdType="pubmed">9314990</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty K.R., Toews G.B., Travis W.D., Colby T.V., Kazerooni E.A., Gross B.H., Jain A., Strawderman R.L., Paine R., Flint A., et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur. Respir. J. 2002;19:275&#x2013;283. doi: 10.1183/09031936.02.00182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.02.00182002</ArticleId><ArticleId IdType="pubmed">11866008</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Liu Y., Xu D., Zhang R., Lan L., Xu H. Prediction of the Development of Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in Patients Discharged after Treatment for COVID-19 Pneumonia. Korean J. Radiol. 2020;21:746&#x2013;755. doi: 10.3348/kjr.2020.0215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2020.0215</ArticleId><ArticleId IdType="pmc">PMC7231610</ArticleId><ArticleId IdType="pubmed">32410413</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W., Wu Q., Chen Z., Xiong Z., Wang K., Tian J., Zhang S. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J. Infect. 2020;82:e5&#x2013;e7. doi: 10.1016/j.jinf.2020.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.09.027</ArticleId><ArticleId IdType="pmc">PMC7521372</ArticleId><ArticleId IdType="pubmed">32998036</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil S.V., Gondhali G., Patil R. POST-COVID-19 LUNG FIBROSIS: STUDY OF 600 CASES IN TERTIARY CARE SETTING IN INDIA. Eur. Respir. J. 2021;58:PA3776. doi: 10.1183/13993003.congress-2021.pa3776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.congress-2021.pa3776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A.C., Mouncey P.R., Al-Beidh F., Rowan K.M., Nichol A.D., Arabi Y.M., Annane D., Beane A., van Bentum-Puijk W., Berry L.R., et al. Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl. J. Med. 2021;384:1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach W.J., Thimmesch A.R., Pierce J.T., Pierce J.D. Consequences of hyperoxia and the toxicity of oxygen in the lung. Nurs. Res.Pract. 2011;2011:260482. doi: 10.1155/2011/260482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/260482</ArticleId><ArticleId IdType="pmc">PMC3169834</ArticleId><ArticleId IdType="pubmed">21994818</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasarmidi E., Tsitoura E., Spandidos D.A., Tzanakis N., Antoniou K.M. Pulmonary fibrosis in the aftermath of the COVID-19 era. Exp. Ther. Med. 2020;20:2557&#x2013;2560. doi: 10.3892/etm.2020.8980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.8980</ArticleId><ArticleId IdType="pmc">PMC7401793</ArticleId><ArticleId IdType="pubmed">32765748</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler S.A., Ebner L., Beigelman C., Bridevaux P.-O., Brutsche M., Clarenbach C., Garzoni C., Geiser T.K., Lenoir A., Mancinetti M., et al. Pulmonary function and radiological features four months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study. Eur. Respir. J. 2021;57:2003690. doi: 10.1183/13993003.03690-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03690-2020</ArticleId><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratan L., Tiliscan C., Arama V., Lazar M., Visan A., Ganea O., Trifonescu M.I., Arama S.S., Ion D. COVID-19 associated coagulopathy is correlated with increased age and markers of inflammation response. Rev. Romana Med. Lab. 2021;29:387&#x2013;394. doi: 10.2478/rrlm-2021-0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rrlm-2021-0031</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Fan Y., Alwalid O., Li N., Jia X., Yuan M., Li Y., Cao Y., Gu J., Wu H., et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299:E177&#x2013;E186. doi: 10.1148/radiol.2021203153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., Noel A., Gunning S., Hatrick J., Hamilton S., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2020;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancatella A., Ricci D., Viola N., Sgr&#xf2; D., Santini F., Latrofa F. Subacute Thyroiditis After Sars-COV-2 Infection. J. Clin. Endocrinol. Metab. 2020;105:2367&#x2013;2370. doi: 10.1210/clinem/dgaa276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa276</ArticleId><ArticleId IdType="pmc">PMC7314004</ArticleId><ArticleId IdType="pubmed">32436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubino F., Amiel S.A., Zimmet P., Alberti G., Bornstein S., Eckel R.H., Mingrone G., Boehm B., Cooper M.E., Chai Z., et al. New-Onset Diabetes in Covid-19. N. Engl. J. Med. 2020;383:789&#x2013;790. doi: 10.1056/NEJMc2018688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2018688</ArticleId><ArticleId IdType="pmc">PMC7304415</ArticleId><ArticleId IdType="pubmed">32530585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chippa V., Aleem A., Anjum F. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Post Acute Coronavirus (COVID-19) Syndrome.</Citation><ArticleIdList><ArticleId IdType="pubmed">34033370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V., Flanders S.A., O&#x2019;Malley M., Malani A.N., Prescott H.C. Sixty-Day Outcomes Among Patients Hospitalized with COVID-19. Ann. Intern. Med. 2021;174:576&#x2013;578. doi: 10.7326/M20-5661.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai D.K., Sharma P., Kumar R. Post covid 19 pulmonary fibrosis. Is it real threat? Indian, J. Tuberc. 2020;68:330&#x2013;333. doi: 10.1016/j.ijtb.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7654356</ArticleId><ArticleId IdType="pubmed">34099197</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi B.G., Tanni S.E. Pulmonary fibrosis and follow-up of COVID-19 survivors: An urgent need for clarification. J. Bras. Pneumol. 2021;47:e20210213. doi: 10.36416/1806-3756/e20210213.</Citation><ArticleIdList><ArticleId IdType="doi">10.36416/1806-3756/e20210213</ArticleId><ArticleId IdType="pmc">PMC8979668</ArticleId><ArticleId IdType="pubmed">34495179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos-Silva P., Felix N.S., Silva P.L., Robba C., Battaglini D., Pelosi P., Rocco P.R.M., Cruz F.F. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir. Physiol. Neurobiol. 2020;280:103492. doi: 10.1016/j.resp.2020.103492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2020.103492</ArticleId><ArticleId IdType="pmc">PMC7351052</ArticleId><ArticleId IdType="pubmed">32659271</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha G.E.-S., Al-Gareeb A.I., Saad H.M., Al-Kuraishy H.M. COVID-19 and corticosteroids: A narrative review. Inflammopharmacology. 2022;30:1189&#x2013;1205. doi: 10.1007/s10787-022-00987-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00987-z</ArticleId><ArticleId IdType="pmc">PMC9106274</ArticleId><ArticleId IdType="pubmed">35562628</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins B.F., Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2019;28:190022. doi: 10.1183/16000617.0022-2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0022-2019</ArticleId><ArticleId IdType="pmc">PMC9489066</ArticleId><ArticleId IdType="pubmed">31578210</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Li H., Liu S. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol. Immunol. 2018;99:134&#x2013;144. doi: 10.1016/j.molimm.2018.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.05.003</ArticleId><ArticleId IdType="pubmed">29783158</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 2020;8:807&#x2013;815. doi: 10.1016/S2213-2600(20)30225-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30225-3</ArticleId><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>la Garza C.E.M.-D., Flores-Torres A.S., Garc&#xed;a-Hern&#xe1;ndez M., Castro-Corona M.D.L. Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis. Med. Hypotheses. 2022;160:110774. doi: 10.1016/j.mehy.2022.110774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2022.110774</ArticleId><ArticleId IdType="pmc">PMC8788098</ArticleId><ArticleId IdType="pubmed">35095174</ArticleId></ArticleIdList></Reference><Reference><Citation>Enomoto T., Usuki J., Azuma A., Nakagawa T., Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 2003;123:2007&#x2013;2011. doi: 10.1378/chest.123.6.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.123.6.2007</ArticleId><ArticleId IdType="pubmed">12796182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartelius H., Gaub J., Ingemann Jensen L., Jensen J., Faber V. Computed tomography of the lungs in acquired immunodeficiency syndrome. An early indicator of interstitial pneumonia. Acta Radiol. 1988;29:641&#x2013;644. doi: 10.1177/028418518802900605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/028418518802900605</ArticleId><ArticleId IdType="pubmed">2847770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahidi M.M., Speer M.C., Steele M.P., Brown K.K., Schwarz M.I., Schwartz D.A. Familial pulmonary fibrosis in the United States. Chest. 2002;121:30S. doi: 10.1378/chest.121.3_suppl.30S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.121.3_suppl.30S</ArticleId><ArticleId IdType="pubmed">11893669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>